Q1 Earnings Forecast for APGE Issued By Wedbush

Apogee Therapeutics, Inc. (NASDAQ:APGE) – Wedbush issued their Q1 2026 earnings estimates for shares of Apogee Therapeutics in a research note issued on Monday, May 12th. Wedbush analyst D. Nierengarten anticipates that the company will post earnings of ($0.98) per share for the quarter. Wedbush currently has a “Outperform” rating and a $90.00 target price on the stock. The consensus estimate for Apogee Therapeutics’ current full-year earnings is ($3.09) per share. Wedbush also issued estimates for Apogee Therapeutics’ Q2 2026 earnings at ($1.01) EPS, Q3 2026 earnings at ($1.03) EPS and Q4 2026 earnings at ($1.06) EPS.

Apogee Therapeutics (NASDAQ:APGE) last posted its quarterly earnings data on Monday, May 12th. The company reported ($0.95) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.19) by $0.24.

Several other analysts also recently weighed in on the stock. Citigroup initiated coverage on shares of Apogee Therapeutics in a research note on Thursday, March 13th. They issued a “buy” rating and a $95.00 price target for the company. Guggenheim restated a “buy” rating on shares of Apogee Therapeutics in a research report on Monday, February 10th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Apogee Therapeutics currently has an average rating of “Buy” and an average price target of $94.60.

Apogee Therapeutics Stock Performance

NASDAQ APGE opened at $39.85 on Tuesday. Apogee Therapeutics has a 52-week low of $26.20 and a 52-week high of $63.50. The company has a market capitalization of $1.79 billion, a P/E ratio of -16.47 and a beta of 1.70. The company has a fifty day moving average of $36.59 and a 200-day moving average of $41.39.

Hedge Funds Weigh In On Apogee Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. China Universal Asset Management Co. Ltd. raised its stake in shares of Apogee Therapeutics by 10.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 9,547 shares of the company’s stock valued at $432,000 after acquiring an additional 892 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Apogee Therapeutics by 4.1% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,835 shares of the company’s stock valued at $1,078,000 after acquiring an additional 931 shares during the last quarter. GF Fund Management CO. LTD. purchased a new position in shares of Apogee Therapeutics during the fourth quarter valued at about $43,000. Arizona State Retirement System increased its position in shares of Apogee Therapeutics by 17.3% during the fourth quarter. Arizona State Retirement System now owns 6,517 shares of the company’s stock valued at $295,000 after buying an additional 960 shares during the period. Finally, New York State Common Retirement Fund lifted its holdings in Apogee Therapeutics by 8.9% in the fourth quarter. New York State Common Retirement Fund now owns 12,187 shares of the company’s stock worth $552,000 after buying an additional 1,000 shares during the period. 79.04% of the stock is owned by institutional investors.

Insider Buying and Selling at Apogee Therapeutics

In other news, insider Carl Dambkowski sold 1,590 shares of the company’s stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $30.48, for a total transaction of $48,463.20. Following the completion of the transaction, the insider now directly owns 251,033 shares of the company’s stock, valued at approximately $7,651,485.84. This represents a 0.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Michael Thomas Henderson sold 10,000 shares of the company’s stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $30.15, for a total transaction of $301,500.00. Following the transaction, the chief executive officer now directly owns 1,292,987 shares of the company’s stock, valued at approximately $38,983,558.05. This trade represents a 0.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 18,175 shares of company stock worth $587,191 over the last three months. Company insiders own 36.10% of the company’s stock.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.